Potential role for Nrf2 activation in the therapeutic effect of MG132 on diabetic nephropathy in OVE26 diabetic mice (Q45775555)

15 December 2017

title

Potential role for Nrf2 activation in the therapeutic effect of MG132 on diabetic nephropathy in OVE26 diabetic mice (English)

1 reference

15 December 2017

1 reference

11

1 reference

15 December 2017

author name string

Wenpeng Cui

1

1 reference

15 December 2017

Bing Li

2

1 reference

15 December 2017

Yang Bai

3

1 reference

15 December 2017

Xiao Miao

4

1 reference

15 December 2017

Qiang Chen

5

1 reference

15 December 2017

Weixia Sun

6

1 reference

15 December 2017

Yi Tan

7

1 reference

15 December 2017

Ping Luo

8

1 reference

15 December 2017

Chi Zhang

9

1 reference

15 December 2017

Shirong Zheng

10

1 reference

15 December 2017

Lining Miao

12

1 reference

15 December 2017

Lu Cai

13

1 reference

15 December 2017

publication date

6 November 2012

1 reference

15 December 2017

American Journal of Physiology - Endocrinology and Metabolism

published in

1 reference

15 December 2017

volume

304

1 reference

15 December 2017

issue

1

1 reference

15 December 2017

page(s)

E87-99

1 reference

15 December 2017

Deletion of angiotensin II type 1 receptor gene or scavenge of superoxide prevents chronic alcohol-induced aortic damage and remodelling

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Zinc supplementation decreases oxidative stress, incidence of infection, and generation of inflammatory cytokines in sickle cell disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Comprehensive proteomic and transcriptomic analysis reveals early induction of a protective anti-oxidative stress response by low-dose proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Diabetic cardiomyopathy and its prevention by metallothionein: experimental evidence, possible mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Increasing expression of heme oxygenase-1 by proteasome inhibition protects astrocytes from heme-mediated oxidative injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Structure and functions of the 20S and 26S proteasomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Nrf2 activators as attractive therapeutics for diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Protective effects of magnesium lithospermate B against diabetic atherosclerosis via Nrf2-ARE-NQO1 transcriptional pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Reactive oxygen species-regulated signaling pathways in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Prevention of diabetic complications by activation of Nrf2: diabetic cardiomyopathy and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

The ubiquitin-proteasome proteolytic pathway in heart vs skeletal muscle: effects of acute diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Prevention of diabetic nephropathy in rats through enhanced renal antioxidative capacity by inhibition of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Alterations of proteasome activities in skeletal muscle tissue of diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Nrf2 and NF-κB modulation by sulforaphane counteracts multiple manifestations of diabetic neuropathy in rats and high glucose-induced changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Bardoxolone methyl and kidney function in CKD with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Cell lines with extended in vitro growth potential from human renal proximal tubule: characterization, response to inducers, and comparison with established cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

The proteasome inhibitor MG132 induces nuclear translocation of erythroid transcription factor Nrf2 and cyclooxygenase-2 expression in human vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Fluvastatin prevents nephropathy likely through suppression of connective tissue growth factor-mediated extracellular matrix accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Cardiac metallothionein synthesis in streptozotocin-induced diabetic mice, and its protection against diabetes-induced cardiac injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Proteasome inhibitors remarkably prevent translesion replication in cancer cells but not normal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Mechanism of the Nrf2/Keap1/ARE signaling system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Diabetic nephropathy in humans: pathologic diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Proteasome-dependent degradation of guanosine 5'-triphosphate cyclohydrolase I causes tetrahydrobiopterin deficiency in diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

Development of late-stage diabetic nephropathy in OVE26 diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00430.2012

10.1152/AJPENDO.00430.2012

21 January 2018

Identifiers

DOI

1 reference

15 December 2017

PubMed ID

23132297

1 reference

15 December 2017